Simtuzumab, a monoclonal antibody targeting LOXL2, [276] initially showed promise in preclinical studies but ultimately failed to demonstrate efficacy in phase II randomized controlled trials for primary sclerosing cholangitis, NASH-related fibrosis, cirrhosis, and HCV/HIV co-infections [276,277,278]. Here, LOXL2 is linked to metabolic dysfunction-associated steatohepatitis.